Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Bioorg Med Chem Lett ; 64: 128678, 2022 05 15.
Article in English | MEDLINE | ID: mdl-35301137

ABSTRACT

nTZDpa kills both growing and persister Staphylococcus aureus. However, due to toxicity liabilities, our lab conducted two structure-activity relationship (SAR) studies focusing on the core scaffold and obtained a new lead compound that was more potent and less hemolytic. Despite these favorable changes, the new lead displayed toxicity to renal cells. In this SAR study, we sought to improve this renal toxicity by derivatization via changes to sp3 character, the acid moiety, and halogenation of the aryl rings. Presented herein are our efforts that produced potent compounds albeit with no improvement to renal cell toxicity.


Subject(s)
Anti-Infective Agents , Staphylococcal Infections , Anti-Bacterial Agents/pharmacology , Humans , Microbial Sensitivity Tests , PPAR gamma , Staphylococcus aureus , Structure-Activity Relationship
2.
ACS Infect Dis ; 6(1): 74-79, 2020 01 10.
Article in English | MEDLINE | ID: mdl-31663323

ABSTRACT

Targeting Streptococcus mutans is the primary focus in reducing dental caries, one of the most common maladies in the world. Previously, our groups discovered a potent bactericidal biaryl compound that was inspired by the natural product honokiol. Herein, a structure activity relationship (SAR) study to ascertain structural motifs key to inhibition is outlined. Furthermore, mechanism studies show that bacterial membrane disruption is central to the bacterial growth inhibition. During this process, it was discovered that analog C2 demonstrated a 4-fold better therapeutic index compared to the commercially available antimicrobial cetylpyridinium chloride (CPC) making it a viable alternative for oral care.


Subject(s)
Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Biphenyl Compounds/pharmacology , Cetylpyridinium/pharmacology , Lignans/pharmacology , Streptococcus mutans/drug effects , Anti-Bacterial Agents/isolation & purification , Bacterial Outer Membrane/drug effects , Biphenyl Compounds/chemistry , Lignans/chemistry , Microbial Sensitivity Tests , Microbiota/drug effects , Phenols/isolation & purification , Phenols/pharmacology , Streptococcus mutans/growth & development
3.
Proc Natl Acad Sci U S A ; 116(33): 16529-16534, 2019 08 13.
Article in English | MEDLINE | ID: mdl-31358625

ABSTRACT

Treatment of Staphylococcus aureus infections is complicated by the development of antibiotic tolerance, a consequence of the ability of S. aureus to enter into a nongrowing, dormant state in which the organisms are referred to as persisters. We report that the clinically approved anthelmintic agent bithionol kills methicillin-resistant S. aureus (MRSA) persister cells, which correlates with its ability to disrupt the integrity of Gram-positive bacterial membranes. Critically, bithionol exhibits significant selectivity for bacterial compared with mammalian cell membranes. All-atom molecular dynamics (MD) simulations demonstrate that the selectivity of bithionol for bacterial membranes correlates with its ability to penetrate and embed in bacterial-mimic lipid bilayers, but not in cholesterol-rich mammalian-mimic lipid bilayers. In addition to causing rapid membrane permeabilization, the insertion of bithionol increases membrane fluidity. By using bithionol and nTZDpa (another membrane-active antimicrobial agent), as well as analogs of these compounds, we show that the activity of membrane-active compounds against MRSA persisters positively correlates with their ability to increase membrane fluidity, thereby establishing an accurate biophysical indicator for estimating antipersister potency. Finally, we demonstrate that, in combination with gentamicin, bithionol effectively reduces bacterial burdens in a mouse model of chronic deep-seated MRSA infection. This work highlights the potential repurposing of bithionol as an antipersister therapeutic agent.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cell Membrane/drug effects , Drug Repositioning , Methicillin-Resistant Staphylococcus aureus/drug effects , Animals , Bithionol/pharmacology , Cell Membrane Permeability/drug effects , Cholesterol/chemistry , Disease Models, Animal , Drug Synergism , Gentamicins/pharmacology , Lipid Bilayers/chemistry , Membrane Fluidity/drug effects , Methicillin-Resistant Staphylococcus aureus/ultrastructure , Molecular Dynamics Simulation , Phosphatidylcholines/chemistry , Structure-Activity Relationship , Unilamellar Liposomes
4.
ACS Infect Dis ; 4(11): 1540-1545, 2018 11 09.
Article in English | MEDLINE | ID: mdl-30132650

ABSTRACT

Conventional antibiotics are not effective in treating infections caused by drug-resistant or persistent nongrowing bacteria, creating a dire need for the development of new antibiotics. We report that the small molecule nTZDpa, previously characterized as a nonthiazolidinedione peroxisome proliferator-activated receptor gamma partial agonist, kills both growing and persistent Staphylococcus aureus cells by lipid bilayer disruption. S. aureus exhibited no detectable development of resistance to nTZDpa, and the compound acted synergistically with aminoglycosides. We improved both the potency and selectivity of nTZDpa against MRSA membranes compared to mammalian membranes by leveraging synthetic chemistry guided by molecular dynamics simulations. These studies provide key insights into the design of selective and potent membrane-active antibiotics effective against bacterial persisters.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Discovery , Indoles/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Sulfides/pharmacology , Erythrocytes/drug effects , Humans , Lipid Bilayers/metabolism , Microbial Sensitivity Tests , Staphylococcus aureus/drug effects
6.
J Org Chem ; 82(23): 12257-12266, 2017 12 01.
Article in English | MEDLINE | ID: mdl-29086565

ABSTRACT

The pentacyclic alkaloid calothrixin B (1) has been synthesized in 5 steps from murrayaquinone A (9). The key step involved the union of boryl aniline 31 with brominated murrayaquinone A (26). In this transformation, alkylquinone 26 undergoes tautomerization to a quinone methide, which is intercepted by boryl aniline 31 to forge a new C-N bond. An intramolecular Suzuki coupling, followed by dehydrogenative aromatization, completed the synthesis of calothrixin B. Subsequent N-oxidation of calothrixin B delivered calothrixin A. The successful synthesis of these alkaloids and the challenges that led to the development of the final synthesis plan are reported herein.


Subject(s)
Benzoquinones/chemistry , Indole Alkaloids/chemical synthesis , Amination , Indole Alkaloids/chemistry , Molecular Structure
7.
Inorg Chem ; 56(10): 5911-5917, 2017 May 15.
Article in English | MEDLINE | ID: mdl-28471188

ABSTRACT

We report a new family of preorganized bis-lactam-1,10-phenanthroline (BLPhen) complexants that possess both hard and soft donor atoms within a convergent cavity and show unprecedented extraction strength for the trivalent f-block metal ions. BLPhen ligands with saturated and unsaturated δ-lactam rings have notable differences in their affinity and selectivity for Am(III) over Eu(III), with the latter being the most selective mixed N,O-donor extractant of Am(III) reported to date. Saturated BLPhen was crystallized with five Ln(III) nitrates to form charge-neutral 1:1 complexes in the solid state. DFT calculations further elaborate on the variety of effects that dictate the performance of these preorganized compounds.

SELECTION OF CITATIONS
SEARCH DETAIL
...